Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipel...

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on MedCity News .

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S.

Adalta Ltd. is outlicensing all of its internal products and focusing instead on inlicensing early stage T-cell assets from Asia, mostly from China, Adalta CEO Tim Oldham told BioWorld. Dubbed its “East to West” strategy, Adalta is integrating Asia's prowess in T-cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting Eastern innovation in cellular immunotherapies with Western regulated markets and patients.

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

Investing.com - The recent rally in Hong Kong-listed biotechs, fueled by fund flows and outlicensing expectations, has been too rapid according to investors, with focus now shifting to clinical research organizations (CROs), Macquarie reports. Macquarie analysts note that the recent biotech rally has primarily benefited thinly-traded small caps, deviating from traditional biotech investing which typically focuses on pipeline developments and regulatory catalysts. While China biopharma outlicensing has attracted generalist investors due to high-profile deals, Macquarie cautions that predicting which companies will secure valuable licensing deals is "exceedingly difficult, if not impossible." The firm highlights that most licensing deals from Chinese companies are small in value and rarely affect licensors’ long-term financial performance. Additionally, most outlicensed assets ultimately fail in clinical trials, regulatory review, or commercial launch, further complicating investment decisions in the sector. China’s domestic environment remains challenging for most biopharmacos, with tight national insurance budgets, price-cutting schemes, and anti-corruption campaigns creating ongoing pressure. Macquarie does not expect these conditions to improve soon, recommending investors focus on proven long-term biotechs instead. In response to market conditions, Macquarie has adjusted its recommendations, now favoring Hansoh at the top position, followed by BeOne and Akeso in dual second place. The firm notes that some investors now view clinical trial outsourcing CROs as potential beneficiaries of licensing deals and the reopening of Hong Kong’s IPO window. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Lexaria (NASDAQ:LEXX) launched Reformulated: Into the Mainstream, an ongoing investor video series to increase transparency and engagement with shareholders.The inaugural episode features CEO Rich Christopher discussing the DehydraTECH platform, applicability across GLP-1 therapies, CBD and antivirals, the ~$75 billion GLP-1 market in 2025, completion of five human GLP-1 studies, and outlicensing activity under an active Material Transfer Agreement with a global pharmaceutical company.

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and patent expirations continue to rise.